Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech Stock
Biotech
Gone are the bear days for biotech? William Blair thinks so
The analyst’s optimism is rooted in continued M&A activity, with 2025's biopharma deal volume the highest recorded in the last decade.
Gabrielle Masson
Dec 12, 2025 10:55am
Pliant terminates lung disease trial due to adverse events
Mar 3, 2025 11:30am
Why biotechs can benefit from the 'rational' IPO environment
Jan 24, 2025 10:30am
Galectin's stock halves after phase 3 MASH trial misses goal
Dec 20, 2024 2:40pm
Lumos stock rockets on oral growth hormone phase 2 results
Nov 8, 2023 9:40am
Enochian distances itself from co-founder amid short attack
Jun 2, 2022 10:53am
